Avacopan Patent Expiration

Avacopan is Used for treating severe active ANCA-associated vasculitis in adult patients in combination with standard therapy. It was first introduced by Chemocentryx Inc in its drug Tavneos on Oct 7, 2021.


Avacopan Patents

Given below is the list of patents protecting Avacopan, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tavneos US11603356 Amorphous form of a complement component C5a receptor May 29, 2041 Chemocentryx
Tavneos US11951214 Capsule formulations Nov 27, 2039 Chemocentryx
Tavneos US8445515 C5aR antagonists Feb 03, 2031 Chemocentryx
Tavneos US8906938 C5aR antagonists Dec 21, 2029 Chemocentryx


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Avacopan's patents.

Given below is the list recent legal activities going on the following patents of Avacopan.

Event Date Patent/Publication
Patent litigations
Email Notification 16 Apr, 2024 US11951214
Change in Power of Attorney (May Include Associate POA) 16 Apr, 2024 US11951214
Change in Power of Attorney (May Include Associate POA) 12 Apr, 2024 US8445515
Change in Power of Attorney (May Include Associate POA) 12 Apr, 2024 US8906938
Email Notification 12 Apr, 2024 US8445515
Email Notification 12 Apr, 2024 US8906938
Mail Patent eGrant Notification 09 Apr, 2024 US11951214
Patent eGrant Notification 09 Apr, 2024 US11951214
Recordation of Patent eGrant 09 Apr, 2024 US11951214
Email Notification 09 Apr, 2024 US11951214



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳